ZYBERNO
Stock Report
Updated Aug 30, 2026

Verastem, Inc. (VSTM)

Healthcare • NASDAQ

$7.22

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
30.0/100
WEAK BUSINESS
Verastem, Inc. (VSTM) scores 30/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-467.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.10x)
Operating Margin (Operational Efficiency):CRITICAL (-221.5%)
Return on Capital (Capital Efficiency):CRITICAL (-170.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Verastem, Inc. (VSTM) stock report — Zyberno Score 30/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:7.22
Market Cap:$722.84M

Valuation Multiples (3)

P/B Ratio:14.46x
P/S Ratio:10.02x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$589.10M

Price Action & Momentum (3)

Momentum Percentile:30 / 100
% of 52-Week High:64.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-94.5%
Reinvestment Rate:0.6%
Fundamental Growth Rate (g):-1.0%

Margin Analysis (3)

Operating Margin Ttm:-221.5%
Net Margin Ttm:-281.0%
Ebitda Margin:-219.3%

TTM Performance (2)

Operating Margin Ttm:-221.5%
Net Margin Ttm:-281.0%

Yield Metrics (2)

Earnings Yield:-$32.37
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:57.1%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):74.8%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.25x
Quick Ratio:2.22x
Cash Ratio:1.75x

Leverage Analysis (3)

Debt To Equity Ttm:0.10x
Debt-to-Equity Ratio:0.10x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-125.37x
Times Interest Earned:-125.37

Capital Structure (4)

Working Capital:98,025,000.00
Cash And Cash Equivalents:136,353,000.00
Long Term Debt:$2.12M
Net Debt:-$133.74M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $72.13M
Linear Growth: 74.8%
📊 Click to view full VSTM Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$159.80M

Bottom Line Performance (3)

-$202.70M
Income Before Tax:-$33.86M
Ebitda Ttm:-158,196,000.00

Operating Expenses (5)

Operating Expenses:247,324,000.00
R And D Expense:140,217,000.00
Sga Expense:95,163,000.00
Income Tax Expense:$816.00K
Interest Expense:1,357,000.00

Expense Ratios (3)

R And D To Revenue Percentage:349.9%
Sga To Revenue Percentage:237.4%
Ebitda Margin:-219.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$206.51M
Current Assets:$176.16M
Ppe Net:1,622,000.00
Goodwill:0.00
Intangible Assets:$15.87M

Liability Structure (4)

Total Liabilities:156,525,000.00
Current Liabilities:78,130,000.00
Long Term Debt:$2.12M
Short Term Debt:$493.00K

Equity & Capital (3)

Equity:$49.99M
Retained Earnings:-$1.24B
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:28,874,000.00
Inventory:2,396,000.00
Accounts Payable:54,196,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,430,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$150.95M-$150.98M

Investment Activities (2)

Investing Cash Flow:-$16.02M
Capital Expenditures Ttm:28,000.00

Financing Activities (3)

Financing Cash Flow:$28.69M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:196,976,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$42.58M

Non-Cash Items (1)

Depreciation Amortization Ttm:1,602,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.39
-$2.25
Earnings Per Share Ttm:-$2.02

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.72
Operating Cash Flow Per Share:-$1.37

Book Value & Capital (2)

Book Value Per Share:$0.50
Cash Per Share:1.36

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.34x
Working Capital Turnover Ttm:0.74x

Receivables Management (2)

Receivables Turnover Ttm:2.50x
Days Sales Outstanding Ttm:146.12

Inventory Management (2)

Inventory Turnover Ttm:30.10x
Days Inventory Outstanding Ttm:12.12

Payables & Cash Cycle (2)

Days Payable Outstanding:274.26
Cash Conversion Cycle:-116.02
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.6%
Fundamental Growth Rate (g):-1.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):74.8%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-12.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:VSTM
Company Name:Verastem, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:100.12M
Shares Outstanding Basic:100.12M
Shares Outstanding Diluted:100.12M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 22:36:47 UTC
Data Timestamp:2026-08-18T02:18:17.773737
Scroll to Top